A woman holds a small bottle that reads “Coronavirus COVID-19 Vaccine” and a medical syringe in front of the Pfizer logo displayed in this image dated October 30, 2020.
Given Ruvic | Reuters
Pfizer announced on Tuesday that it would apply to German drug manufacturer BioNTech for full US approval of its Covid-19 vaccine at the end of this month. If the FDA signs out, the company can market the shot directly to consumers.
When it released its first quarter financial results, the company reported first quarter sales of $ 3.5 billion on its Covid-19, generating profits and sales that exceeded Wall Street expectations.
According to Refinitiv’s average estimates, Pfizer has outperformed Wall Street expectations as follows:
- Adjusted EPS: 93 cents per share compared to 77 cents expected
- Revenue: $ 14.58 billion versus $ 13.51 billion expected
The company now expects total annual sales of the vaccine to be $ 26 billion, compared to its previous forecast of approximately $ 15 billion.
Pfizer shares rose 1.4% after the news.
This is a developing story. Please try again.